Page last updated: 2024-11-06

trovafloxacin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Trovafloxacin is a synthetic fluoroquinolone antibiotic that was developed for the treatment of bacterial infections. It was withdrawn from the market in 1998 due to safety concerns, including the risk of hepatotoxicity. Trovafloxacin is a potent inhibitor of bacterial DNA gyrase and topoisomerase IV, essential enzymes for bacterial DNA replication and repair. The drug is a chiral molecule, with the S-enantiomer exhibiting greater antibacterial activity than the R-enantiomer. Trovafloxacin is well-absorbed following oral administration and achieves therapeutic concentrations in various tissues, including the lungs, liver, and kidneys. It is primarily metabolized by the liver and excreted in the urine. Trovafloxacin has been studied extensively for its potential as a treatment for various bacterial infections, including pneumonia, urinary tract infections, and skin infections. However, its use was limited due to its adverse effects, including hepatotoxicity, tendonitis, and photosensitivity. The development of trovafloxacin highlighted the importance of thorough safety testing and the need for careful monitoring of patients treated with fluoroquinolone antibiotics. Further research on trovafloxacin focuses on understanding the mechanisms of its toxicity and exploring potential strategies for safer use.'

trovafloxacin: a trifluoronaphthyridone derivative of 7-(3-azabicyclo(3.1.0)hexyl)naphthyridone; has antineoplastic activity [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

trovafloxacin : A 1,8-naphthyridine derivative that is 4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid bearing additional 2,4-difluorophenyl, fluoro and 6-amino-3-azabicyclo[3.1.0]hex-3-yl substituents at positions 1, 6 and 7 respectively. A broad-spectrum antibiotic that was withdrawn from the market due to risk of liver failure. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

glucoraphenin : A glucosinolic acid that consists of 1-thio-beta-D-glucopyranose attached to a 1-(methylsulfinyl)-5-[(sulfooxy)imino]pent-1-en-5-yl group at the anomeric sulfur. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID62959
CHEMBL ID428
CHEBI ID9763
SCHEMBL ID34465
SCHEMBL ID34466
SCHEMBL ID9177464
MeSH IDM0214301
PubMed CID5281138
MeSH IDM0214301

Synonyms (61)

Synonym
CHEMBL428
chebi:9763 ,
7-((1r,5s)-6-amino-3-aza-bicyclo[3.1.0]hex-3-yl)-1-(2,4-difluoro-phenyl)-6-fluoro-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid
cp-99219
trovafloxacin [inn]
cp-99,219
tvfx
fluorinated quinolone
(1alpha,5alpha,6alpha)-7-(6-amino-3-azabicyclo[3.1.0]hex-3-yl)-1-(2,4-difluorophenyl)-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid
cp99219
7-[(1s,5r)-6-amino-3-azabicyclo[3.1.0]hexan-3-yl]-1-(2,4-difluorophenyl)-6-fluoro-4-oxo-1,8-naphthyridine-3-carboxylic acid
1,8-naphthyridine-3-carboxylic acid, 7-(6-amino-3-azabicyclo[3.1.0]hex-3-yl)-1-(2,4-difluorophenyl)-6-fluoro-1,4-dihydro-4-oxo-, (1alpha,5alpha,6alpha)-
trovan (oral)
C07664
147059-72-1
trovafloxacin
DB00685
7-[(1r,5s,6s)-6-amino-3-azabicyclo[3.1.0]hex-3-yl]-1-(2,4-difluorophenyl)-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid
AKOS000277872
7-[(1r,5s)-6-amino-3-azabicyclo[3.1.0]hexan-3-yl]-1-(2,4-difluorophenyl)-6-fluoro-4-oxo-1,8-naphthyridine-3-carboxylic acid
D08654
trovafloxacin (inn)
unii-9f388j00uk
9f388j00uk ,
trovafloxacin [mi]
7-((1r,5s,6s)-6-amino-3-azabicyclo(3.1.0)hex-3-yl)-1-(2,4-difluorophenyl)-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid
1,8-naphthyridine-3-carboxylic acid, 7-(6-amino-3-azabicyclo(3.1.0)hex-3-yl)-1-(2,4-difluorophenyl)-6-fluoro-1,4-dihydro-4-oxo-(1.alpha.,5.alpha.,6.alpha.)-
trovafloxacin [ema epar]
trovafloxacin [who-dd]
trovafloxacin [vandf]
AKOS015909896
WVPSKSLAZQPAKQ-CDMJZVDBSA-N
SCHEMBL34465
SCHEMBL34466
TR6 ,
trovafloxacinum
trovafloxacino
trovafloxacine
SCHEMBL9177464
DTXSID0041145
7-[(1r,5s)-6-amino-3-azabicyclo[3.1.0]hexan-3-yl]-1-(2,4-difluorophenyl)-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid
EX-A897
Z2587996506
7-((1r,5s,6s)-6-amino-3-azabicyclo[3.1.0]hexan-3-yl)-1-(2,4-difluorophenyl)-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid
1,8-naphthyridine-3-carboxylic acid, 7-[(1alpha,5alpha,6alpha)-6-amino-3-azabicyclo[3.1.0]hex-3-yl]-1-(2,4-difluorophenyl)-6-fluoro-1,4-dihydro-4-oxo-
rel-7-((1r,5s,6s)-6-amino-3-azabicyclo[3.1.0]hexan-3-yl)-1-(2,4-difluorophenyl)-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid
mfcd00871697
BCP12644
Q544393
1,8-naphthyridine-3-carboxylic acid, 7-(1.alpha.,5.alpha.,6.alpha.)-6-amino-3-azabicyclo3.1.0hex-3-yl-1-(2,4-difluorophenyl)-6-fluoro-1,4-dihydro-4-oxo-
A935288
CS-0017509
HY-A0170
7-[(1r,5s,6s)-6-amino-3-azabicyclo[3.1.0]hexan-3-yl]-1-(2,4-difluorophenyl)-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid
EN300-7413614
7-[(1r,5s,6r)-6-amino-3-azabicyclo[3.1.0]hexan-3-yl]-1-(2,4-difluorophenyl)-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid
GLXC-25514
AC-36823
glucoraphenin
C08420
[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] (e)-5-methylsulfinyl-n-sulfooxypent-4-enimidothioate

Research Excerpts

Overview

Trovafloxacin (TVX) is a fluoroquinolone antibiotic known to cause idiosyncratic, drug-induced liver injury (IDILI) in humans. The drug was withdrawn from the market relatively soon after its release due to the risk of hepatotoxicity.

ExcerptReferenceRelevance
"Trovafloxacin is a broad-spectrum antibiotic, recently identified as an inhibitor of pannexin-1 (Panx1) channels. "( Trovafloxacin attenuates neuroinflammation and improves outcome after traumatic brain injury in mice.
Calderon, F; Contreras, JE; Garg, C; Loh, JM; Ramachandran, J; Seo, JH, 2018
)
3.37
"Trovafloxacin (TVX) is a fluoroquinolone antibiotic known to cause idiosyncratic, drug-induced liver injury (IDILI) in humans. "( Trovafloxacin potentiation of lipopolysaccharide-induced tumor necrosis factor release from RAW 264.7 cells requires extracellular signal-regulated kinase and c-Jun N-Terminal Kinase.
Albee, RP; Ganey, PE; Poulsen, KL; Roth, RA, 2014
)
3.29
"Trovafloxacin (TVX) is a drug that has caused idiosyncratic, drug-induced liver injury (IDILI) in humans. "( Trovafloxacin enhances lipopolysaccharide-stimulated production of tumor necrosis factor-α by macrophages: role of the DNA damage response.
Beggs, KM; Ganey, PE; Olivero-Verbel, J; Poulsen, KL; Roth, RA, 2014
)
3.29
"Trovafloxacin is an antibiotic that was withdrawn from the market relatively soon after its release due to the risk of hepatotoxicity. "( Acyl-glucuronide as a Possible Cause of Trovafloxacin-Induced Liver Toxicity: Induction of Chemokine (C-X-C Motif) Ligand 2 by Trovafloxacin Acyl-glucuronide.
Fujie, Y; Fujiwara, R; Itoh, T; Mitsugi, R; Sumida, K; Tukey, RH, 2016
)
2.14
"Trovafloxacin (TVX) is a fluoroquinolone antibiotic whose therapeutic use was severely restricted due to an unacceptable risk of idiosyncratic liver injury. "( Trovafloxacin, a fluoroquinolone antibiotic with hepatotoxic potential, causes mitochondrial peroxynitrite stress in a mouse model of underlying mitochondrial dysfunction.
Boelsterli, UA; Hsiao, CJ; Younis, H, 2010
)
3.25
"Trovafloxacin is an expanded spectrum, newer-generation fluoroquinolone antibiotic with improved Gram-positive and anaerobic activity compared with existing quinolones, while maintaining Gram-negative activity comparable to ciprofloxacin. "( Ocular toxicity of intravitreal trovafloxacin in the pigmented rabbit.
Au Eong, KG; Green, WR; Joo, MJ; Ng, EW; O'Brien, TP, 2003
)
2.05
"Trovafloxacin (Trovan) is a fluoroquinolone antibiotic drug with a long half-life and broad-spectrum activity. "( In vitro metabolism of a model cyclopropylamine to reactive intermediate: insights into trovafloxacin-induced hepatotoxicity.
Foss, FW; Macdonald, TL; Sun, Q; Zhu, R, 2008
)
2.01
"Trovafloxacin (CP-99,219) is a new fluoroquinolone antibacterial agent with a broad spectrum of activity against Gram-positive and Gram-negative bacteria. "( Pharmacokinetics and safety of trovafloxacin (CP-99,219), a new quinolone antibiotic, following administration of single oral doses to healthy male volunteers.
Foulds, G; Harris, SC; Liston, TE; Nix, DE; Schentag, JJ; Teng, R, 1995
)
2.02
"Trovafloxacin is an effective antimicrobial agent against Legionella in vitro and in vivo, with the ability to concentrate in macrophages and kill intracellular organisms."( Activity of trovafloxacin (CP-99,219) against Legionella isolates: in vitro activity, intracellular accumulation and killing in macrophages, and pharmacokinetics and treatment of guinea pigs with L. pneumophila pneumonia.
Edelstein, MA; Edelstein, PH; Gladue, RP; Polzer, R; Ren, J, 1996
)
1.39
"Trovafloxacin was found to be a typical quinolone producing a biphasic dose response against Escherichia coli, Staphylococcus aureus or Streptococcus pneumoniae. "( Bactericidal activity of trovafloxacin (CP-99,219).
Morrissey, I, 1996
)
2.04
"Trovafloxacin (CP-99,219) is a new quinolone antibacterial characterized by a novel 3-azabicyclo[3.1.0]hexyl substituent at the C-7 position, which was discovered in the course of a programme targeting improved activity compared with ciprofloxacin against Gram-positive aerobic organisms and anaerobes, as well as an extended elimination half-life."( The chemistry and biological profile of trovafloxacin.
Brighty, KE; Gootz, TD, 1997
)
1.29
"Trovafloxacin is a fluoroquinolone antibacterial agent with a broad spectrum of activity. "( Trovafloxacin.
Haria, M; Lamb, HM, 1997
)
3.18
"Trovafloxacin is a new fluoronaphthyridone with enhanced activity against gram-positive cocci and variable activity reported against Enterococcus spp."( Activity of trovafloxacin (with or without ampicillin-sulbactam) against enterococci in an in vitro dynamic model of infection.
Dudley, MN; Gilbert, D; Zinner, SH, 1998
)
1.4
"Trovafloxacin is a new fluoronaphthyridone chemically and functionally related to members of the fluoroquinolone class of antimicrobial agents. "( Efficacy of trovafloxacin against experimental Staphylococcus aureus endocarditis.
Aeschlimann, JR; Houlihan, HH; Kaatz, GW; Mercier, RC; Rybak, MJ; Seo, SM, 1998
)
2.12
"Trovafloxacin is a fluoroquinolone with an exceptionally broad antibacterial spectrum."( New antibiotics.
Friedland, IR; Lutsar, I, 1998
)
1.02
"Trovafloxacin is a novel naphthyridone quinolone with promising activity against S."( Efficacy of trovafloxacin against penicillin-susceptible and multiresistant strains of Streptococcus pneumoniae in a mouse pneumonia model.
Azoulay-Dupuis, E; Bauchet, J; Bédos, JP; Carbon, C; Muffat-Joly, M; Rieux, V, 1998
)
1.4
"Trovafloxacin is a new fluorinated naphthyridone having expanded activity against Gram-positive and anaerobic pathogens compared with ciprofloxacin or levofloxacin or ofloxacin. "( Comparative antimicrobial activity of trovafloxacin tested against 3049 Streptococcus pneumoniae isolates from the 1997-1998 respiratory infection season.
Doern, GV; Jones, RN; Pfaller, MA, 1998
)
2.01
"Trovafloxacin is a new fourth-generation fluoroquinolone whose pharmacokinetics and in vitro activity suggest that it is well suited for antibiotic prophylaxis in elective colorectal surgery. "( Concentrations of trovafloxacin in colonic tissue and peritoneal fluid after intravenous infusion of the prodrug alatrofloxacin in patients undergoing colorectal surgery.
Dogolo, LC; Melnik, G; Schwesinger, WH; Teng, R; Vincent, J, 1998
)
2.08
"Trovafloxacin is a new fourth-generation fluoroquinolone whose pharmacokinetics and in vitro activity suggest that it is well suited for antibiotic prophylaxis in elective hysterectomy."( Oral trovafloxacin compared with intravenous cefoxitin in the prevention of bacterial infection after elective vaginal or abdominal hysterectomy for nonmalignant disease. Trovafloxacin Surgical Group.
Godwin, D; Gordon, S; Hemsell, D; Luke, D; Pearlman, M; Roy, S, 1998
)
2.26
"Trovafloxacin is a new fluoroquinolone with enhanced activity against gram-positive and anaerobic microorganisms. "( Trovafloxacin: a new fluoroquinolone.
Alghasham, AA; Nahata, MC, 1999
)
3.19
"Trovafloxacin is a recently approved fluoroquinolone with excellent activity against gram-positive and gram-negative organisms that offers a potential alternative for treatment of beta-lactam-resistant pneumococcal meningitis. "( Pharmacodynamics of trovafloxacin in experimental pneumococcal meningitis: basis for dosage selection in children with meningitis.
Bastero, R; Friedland, IR; Jafri, HS; Lutsar, I; McCoig, CC; McCracken, GH; Olsen, K; Shelton, S; Wubbel, L, 1999
)
2.07
"Trovafloxacin is a potentially useful agent for treatment of infections caused by cephalosporin-resistant Streptococcus pneumoniae. "( Pharmacodynamics of trovafloxacin in a mouse model of cephalosporin-resistant Streptococcus pneumoniae pneumonia.
Friedland, IR; Ghaffar, F; Jafri, H; Lutsar, I; McCracken, GH; Ng, W; Wubbel, L, 1999
)
2.07
"Trovafloxacin is a new fluoroquinolone that has potent microbiological activity against the pneumococcus, including penicillin-resistant strains. "( Protective effect of trovafloxacin, ciprofloxacin and ampicillin against Streptococcus pneumoniae in a murine sepsis model.
Banevicius, MA; Lacy, MK; Nicolau, DP; Nightingale, CH; Quintiliani, R, 1999
)
2.07
"Trovafloxacin is a novel investigational trifluoronaphthyridone antibiotic with broad-spectrum activity against Gram-positive and Gram-negative organisms. "( Susceptibility of 497 clinical isolates of gram-negative anaerobes to trovafloxacin and eight other antibiotics.
Jamal, WY; Khodakhast, FB; Mokaddas, EM; Rotimi, VO; Sanyal, SC; Verghese, TL, 1999
)
1.98
"Trovafloxacin is a relatively new quinolone for which these side effects have not been described."( Trovafloxacin-induced weakness due to a demyelinating polyneuropathy.
Murray, CK; Wortmann, GW, 2000
)
2.47
"Trovafloxacin is a broad-spectrum synthetic fluoroquinolone used for a wide variety of bacterial infections. "( Trovafloxacin-associated leukopenia.
Angood, PB; Mitropoulos, FA; Rabinovici, R, 2001
)
3.2
"Trovafloxacin is a new fluoroquinolone that exhibits good penetration into the central nervous system and excellent antimicrobial activity against common meningeal pathogens, including beta-lactam-resistant pneumococci."( Quinolone treatment for pediatric bacterial meningitis: a comparative study of trovafloxacin and ceftriaxone with or without vancomycin.
Arguedas, AG; Arrieta, AC; Bradley, J; Falleiros-Carvalho, LH; Feris, JM; Frenck, RW; Hussey, GD; Klugman, KP; Marques, SR; McCoig, C; McCracken, GH; Pancorbo, S; Sáez-Llorens, X; Vargas, SL; Wald, ER, 2002
)
1.98

Effects

Trovafloxacin has a t1/2 of 12 hours, which allows for single daily doses. It is extensively metabolized.

Trovafloxacin has shown to be effective in the treatment of infections due to Chlamydia with excellent clinical results and a good tolerance. It has an increased potential for CNS adverse reactions, notably dizziness.

ExcerptReferenceRelevance
"Trovafloxacin has a t1/2 of 12 hours, which allows for single daily doses, and is extensively metabolized."( Levofloxacin and trovafloxacin: the next generation of fluoroquinolones?
Ernst, EJ; Ernst, ME; Klepser, ME, 1997
)
1.36
"Trovafloxacin has an increased potential for CNS adverse reactions, notably dizziness."( Safety of the new fluoroquinolones compared with ciprofloxacin.
Ball, P, 2000
)
1.03
"Trovafloxacin has similar or 2-fold lower activity than ciprofloxacin against Enterobacteriaceae and Pseudomonas aeruginosa."( Trovafloxacin.
Haria, M; Lamb, HM, 1997
)
2.46
"Trovafloxacin has a t1/2 of 12 hours, which allows for single daily doses, and is extensively metabolized."( Levofloxacin and trovafloxacin: the next generation of fluoroquinolones?
Ernst, EJ; Ernst, ME; Klepser, ME, 1997
)
1.36
"Trovafloxacin has shown to be effective in the treatment of infections due to Chlamydia with excellent clinical results and a good tolerance."( [Trovafloxacin in gynecology].
Provenzano, SL, 1999
)
1.93
"Trovafloxacin has an increased potential for CNS adverse reactions, notably dizziness."( Safety of the new fluoroquinolones compared with ciprofloxacin.
Ball, P, 2000
)
1.03

Actions

Trovafloxacin also showed lower MIC50 values (0.12-0.25 microgram/ml) than ciprofloxac in E. coli.

ExcerptReferenceRelevance
"Trovafloxacin also showed lower MIC50 values (0.12-0.25 microgram/ml) than ciprofloxacin (MIC50 of 0.5-1 microgram/ml) for E."( Susceptibility of ciprofloxacin-resistant staphylococci and enterococci to trovafloxacin.
Bonilla, HF; Bradley, SF; Kauffman, CA; Zarins, LT, 1996
)
1.25
"Trovafloxacin displays exceptional antimicrobial potency against pathogens associated with community-acquired meningitis. "( Postantibiotic effect of trovafloxacin against Streptococcus pneumoniae, Haemophilus influenzae, and Neisseria meningitidis in cerebrospinal fluid and broth culture media.
Nicolau, DP; Nightingale, CH; Tessier, PR, 2000
)
2.05

Treatment

ExcerptReferenceRelevance
"Trovafloxacin treatment of CCI-injured mice significantly reduced tissue damage markers and improved locomotor deficits. "( Trovafloxacin attenuates neuroinflammation and improves outcome after traumatic brain injury in mice.
Calderon, F; Contreras, JE; Garg, C; Loh, JM; Ramachandran, J; Seo, JH, 2018
)
3.37

Toxicity

The most common treatment-related adverse events in studies were nausea, headache, insertion site reaction, and dizziness. Trovafloxacin recipients were also more than twice as likely to discontinue treatment due to adverse events than moxifl Oxacin-treated patients. Although the complete mechanism of trovaf loxacins-induced liver injury is still unknown, trovf loxacs can be involved in the development of toxic reactions in vitro and in vivo.

ExcerptReferenceRelevance
" Adverse events were recorded in 112 (12."( Safety of trovafloxacin in treatment of lower respiratory tract infections.
Hopkins, S; Williams, D, 1998
)
0.7
" The most common treatment-related adverse events in studies of intravenous alatrofloxacin followed by oral trovafloxacin were nausea, headache, insertion site reaction, and dizziness."( Safety and tolerability of intravenous-to-oral treatment and single-dose intravenous or oral prophylaxis with trovafloxacin.
Hopkins, S; Williams, DJ, 1998
)
0.72
"In this large patient sample, intravenous alatrofloxacin followed by oral trovafloxacin was safe and well tolerated."( Safety and tolerability of intravenous-to-oral treatment and single-dose intravenous or oral prophylaxis with trovafloxacin.
Hopkins, S; Williams, DJ, 1998
)
0.74
" Comparable incidences of adverse events, mainly mild or moderate in intensity, were experienced in each treatment group."( Treatment of complicated intra-abdominal infections: comparison of the tolerability and safety of intravenous/oral trovafloxacin versus intravenous imipenem/cilastatin switching to oral amoxycillin/clavulanic acid.
Luke, DR; Peterson, J,
)
0.34
" Ciprofloxacin is well tolerated; the incidence of adverse events is low and serious adverse events are rare."( Safety of the new fluoroquinolones compared with ciprofloxacin.
Ball, P, 2000
)
0.31
"This paper focuses on the development of four major adverse drug reactions (ADRs) associated with some fluoroquinolones: convulsions, phototoxicity, cardiac effects, and hepatotoxicity."( Latest industry information on the safety profile of levofloxacin in Japan.
Yagawa, K, 2001
)
0.31
" Trovafloxacin recipients were also more than twice as likely to discontinue treatment due to adverse events than moxifloxacin-treated patients."( Comparison of the efficacy and safety of moxifloxacin and trovafloxacin for the treatment of acute, bacterial maxillary sinusitis in adults.
Arvis, P; Klossek, JM; Leberre, MA; Nikolaidis, P; Siegert, R, 2003
)
1.47
" Findings in animal models have shown that adverse effects of numerous drugs with idiosyncratic hepatotoxicity in humans can be reproduced in the presence of coincident inflammatory cytokine signaling."( Cytokine-associated drug toxicity in human hepatocytes is associated with signaling network dysregulation.
Alexopoulos, LG; Cosgrove, BD; Griffith, LG; Hang, TC; Hendriks, BS; Lauffenburger, DA; Sorger, PK, 2010
)
0.36
"Idiosyncratic adverse drug reactions (IADRs) occur in a minority of patients yet account for the majority of postmarketing use restrictions by the Food and Drug Administration."( Idiosyncratic drug-induced liver injury and the role of inflammatory stress with an emphasis on an animal model of trovafloxacin hepatotoxicity.
Ganey, PE; Roth, RA; Shaw, PJ, 2010
)
0.57
" An understanding of structure-activity relationships (SARs) of chemicals can make a significant contribution to the identification of potential toxic effects early in the drug development process and aid in avoiding such problems."( Developing structure-activity relationships for the prediction of hepatotoxicity.
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ, 2010
)
0.36
" Herewith, we present a novel 3D liver model for routine testing in 96-well format capable of reducing the risk of unwanted toxic effects in the clinic."( Multi-cell type human liver microtissues for hepatotoxicity testing.
Agarkova, I; Kelm, JM; Messner, S; Moritz, W, 2013
)
0.39
"Many adverse drug reactions are caused by the cytochrome P450 (CYP)-dependent activation of drugs into reactive metabolites."( Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Jones, LH; Nadanaciva, S; Rana, P; Will, Y, 2016
)
0.43
" Although the complete mechanism of trovafloxacin-induced liver injury is still unknown, trovafloxacin acyl-glucuronide can be involved in the development of toxic reactions in vitro and in vivo."( Acyl-glucuronide as a Possible Cause of Trovafloxacin-Induced Liver Toxicity: Induction of Chemokine (C-X-C Motif) Ligand 2 by Trovafloxacin Acyl-glucuronide.
Fujie, Y; Fujiwara, R; Itoh, T; Mitsugi, R; Sumida, K; Tukey, RH, 2016
)
0.98
"The use of fluoroquinolone antibiotics has been restricted in children because of their potential to cause adverse musculoskeletal events."( Assessment of the risk of musculoskeletal adverse events associated with fluoroquinolone use in children: A meta-analysis.
Cui, HR; Hu, YS; Tang, HB; Wang, JG, 2020
)
0.56
"Cochrane Library, Embase, and PubMed databases were used to retrieve studies related to fluoroquinolone and non-fluoroquinolone-induced musculoskeletal adverse events in children."( Assessment of the risk of musculoskeletal adverse events associated with fluoroquinolone use in children: A meta-analysis.
Cui, HR; Hu, YS; Tang, HB; Wang, JG, 2020
)
0.56
" The combined results showed that there was no statistical difference between fluoroquinolone and non-fluoroquinolone groups in terms of musculoskeletal adverse events in children (risk ratio = 1."( Assessment of the risk of musculoskeletal adverse events associated with fluoroquinolone use in children: A meta-analysis.
Cui, HR; Hu, YS; Tang, HB; Wang, JG, 2020
)
0.56
"The results showed that fluoroquinolone and non-fluoroquinolone antibiotics were not different in terms of their ability to cause musculoskeletal adverse events in children."( Assessment of the risk of musculoskeletal adverse events associated with fluoroquinolone use in children: A meta-analysis.
Cui, HR; Hu, YS; Tang, HB; Wang, JG, 2020
)
0.56

Pharmacokinetics

An in vitro pharmacokinetic model was used to simulate the pharmacokinetics of trovafloxacin, ofloxACin, and ciprofloxacins in human serum. The aim of the present study was to investigate the different pharmacodynamic parameters of grepafl Oxacin in comparison with those of troVaflOxacin. The pharmacokinetic profile of tro VFLO was consistent in healthy subjects and individuals who had undergone recent hepatobiliary surgery.

ExcerptReferenceRelevance
" The elimination half-life (T(1/2)) for trovafloxacin was independent of the dose and the mean T(1/2)s for the 100, 200 and 300 mg equivalent doses of alatrofloxacin were 10."( Pharmacokinetics and safety of trovafloxacin in healthy male volunteers following administration of single intravenous doses of the prodrug, alatrofloxacin.
Baris, BA; Friedman, HL; Polzer, RJ; Teng, R; Venitz, J; Vincent, J; Willavize, SA, 1997
)
0.85
" There were no significant differences in mean Cmax or AUC(0-12) between the two groups on day 7 or on day 14, nor were there significant within-group differences on the two days."( Effect of trovafloxacin, a new fluoroquinolone antibiotic, on the steady-state pharmacokinetics of theophylline in healthy volunteers.
Dogolo, LC; Friedman, HL; Teng, R; Vincent, J; Willavize, SA, 1997
)
0.7
" The pharmacokinetic profile of trovafloxacin in serum was consistent in healthy subjects and in individuals who had undergone recent hepatobiliary surgery."( Pharmacokinetics and metabolism of single oral doses of trovafloxacin.
Dalvie, DK; Friedman, HL; Teng, R; Vincent, J, 1998
)
0.83
"When trovafloxacin was coadministered with morphine, the half-life of trovafloxacin was unchanged; however, the ratio of the area under the serum concentration versus time curve (AUC(0-infinity)) estimates for trovafloxacin/morphine versus trovafloxacin/placebo was 63."( The pharmacokinetic effects of coadministration of morphine and trovafloxacin in healthy subjects.
Friedman, HL; Hunt, T; Robarge, L; Teng, R; Vincent, J; Willavize, SA, 1998
)
1.05
"An in vitro pharmacokinetic model was used to simulate the pharmacokinetics of trovafloxacin, ofloxacin, and ciprofloxacin in human serum and to compare their pharmacodynamics against eight Streptococcus pneumoniae strains."( Pharmacodynamics of trovafloxacin, ofloxacin, and ciprofloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model.
Lister, PD; Sanders, CC, 1999
)
0.85
" Using the rabbit meningitis model, we sought to characterize the pharmacodynamic properties of trovafloxacin in the cerebrospinal fluid (CSF)."( Pharmacodynamics of trovafloxacin in experimental pneumococcal meningitis: basis for dosage selection in children with meningitis.
Bastero, R; Friedland, IR; Jafri, HS; Lutsar, I; McCoig, CC; McCracken, GH; Olsen, K; Shelton, S; Wubbel, L, 1999
)
0.85
" We studied the effectiveness of trovafloxacin therapy and examined the correlation between pharmacodynamic indices in serum and lung, and bacterial killing."( Pharmacodynamics of trovafloxacin in a mouse model of cephalosporin-resistant Streptococcus pneumoniae pneumonia.
Friedland, IR; Ghaffar, F; Jafri, H; Lutsar, I; McCracken, GH; Ng, W; Wubbel, L, 1999
)
0.91
" The average half-life is around eleven hours, with an enhanced protein bound that allows to administrate it only once a day."( [Pharmacokinetics of trovafloxacin: its clinical significance].
Biglia, MA; Clara, LO, 1999
)
0.62
" The primary pharmacokinetic parameters (average +/- SD) analyzed were volume of distribution at steady state (1."( Pharmacokinetics of a fluoronaphthyridone, trovafloxacin (CP 99,219), in infants and children following administration of a single intravenous dose of alatrofloxacin.
Bradley, JS; Capparelli, EV; Kearns, GL; Reed, MD; Vincent, J, 2000
)
0.57
"The pharmacokinetic disposition of numerous antimicrobial agents is altered in critically ill patients."( Pharmacokinetics of intravenous trovafloxacin in critically ill adults.
Fish, DN; Olsen, KM; Rebuck, JA; Weidenbach, T, 2000
)
0.59
" The aim of the present study was to investigate the different pharmacodynamic parameters of grepafloxacin in comparison with those of trovafloxacin."( Pharmacodynamic studies of trovafloxacin and grepafloxacin in vitro against Gram-positive and Gram-negative bacteria.
Cars, T; Lowdin, E; Odenholt, I, 2000
)
0.81
"This investigation explored pharmacodynamic characteristics of fluoroquinolones against Bacteroides thetaiotamicron and the potential for development of resistance."( Fluoroquinolone resistance in anaerobic bacteria following exposure to levofloxacin, trovafloxacin, and sparfloxacin in an in vitro pharmacodynamic model.
Hovde, LB; Peterson, ML; Ross, GH; Rotschafer, JC; Wright, DH, 2001
)
0.53
"An in vitro pharmacodynamic investigation was conducted to explore whether the area under the concentration time curve from 0 to 24 h (AUC(0-24))/MIC ratio could predict fluoroquinolone performance against Bacteroides fragilis."( Pharmacodynamics of trovafloxacin and levofloxacin against Bacteroides fragilis in an in vitro pharmacodynamic model.
Brown, GH; Hoang, AD; Hovde, LB; Peterson, ML; Rotschafer, JC; Wright, DH, 2002
)
0.64
" This study suggests that both bacterial strain-independent AUC/MIC- and the respective strain-specific dose-response relationships of the AME are important for comprehensive pharmacodynamic evaluation of antimicrobial agents."( Bacterial strain-independent AUC/MIC and strain-specific dose-response relationships reflecting comparative fluoroquinolone anti-pseudomonal pharmacodynamics in an in vitro dynamic model.
Firsov, AA; Lubenko, IY; Portnoy, YA; Vostrov, SN; Zinner, SH, 2002
)
0.31
"Human pharmacokinetic parameters are often predicted prior to clinical study from in vivo preclinical pharmacokinetic data."( Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
Jolivette, LJ; Ward, KW, 2005
)
0.33
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35

Compound-Compound Interactions

The in vitro activity of trovafloxacin alone and in combination with ceftazidime, meropenem, and amikacin was studied by determining the minimal inhibitory concentrations (MICs) for 111 gram-negative and 71 gram-positive bacteria.

ExcerptReferenceRelevance
"The in vitro activity of trovafloxacin alone and in combination with ceftazidime, meropenem, and amikacin was studied by determining the minimal inhibitory concentrations (MICs) for 111 gram-negative and 71 gram-positive bacteria."( In vitro activity of trovafloxacin in combination with ceftazidime, meropenem, and amikacin.
Milatovic, D; Wallrauch, C, 1996
)
0.92
" Trovafloxacin, a new fluoroquinolone with potent activity against Toxoplasma gondii, was examined for potential synergistic activity when combined with other drugs used for treatment of human toxoplasmosis."( Activity of trovafloxacin in combination with other drugs for treatment of acute murine toxoplasmosis.
Araujo, FG; Khan, AA; Polzer, RJ; Remington, JS; Slifer, T, 1997
)
1.59
" It is concluded that DU-6859a and trovafloxacin are very potent against enterococci, especially when combined with gentamicin."( In vitro activity of quinupristin/dalfopristin and newer quinolones combined with gentamicin against resistant isolates of Enterococcus faecalis and Enterococcus faecium.
Giamarellos-Bourboulis, EJ; Giamarellou, H; Grecka, P; Sambatakou, H, 1998
)
0.58
"This in vitro study evaluated the activities of vancomycin, LY333328, and teicoplanin alone and in combination with gentamicin, rifampin, and RP59500 against Staphylococcus aureus isolates with intermediate susceptibilities to vancomycin."( Evaluation of bactericidal activities of LY333328, vancomycin, teicoplanin, ampicillin-sulbactam, trovafloxacin, and RP59500 alone or in combination with rifampin or gentamicin against different strains of vancomycin-intermediate Staphylococcus aureus by
Aeschlimann, JR; Hershberger, E; Moldovan, T; Rybak, MJ, 1999
)
0.52
"We tested three fluoroquinolones (ciprofloxacin, levofloxacin, and trovafloxacin), each combined with each of four beta-lactams (cefoperazone, ceftriaxone, imipenem, and meropenem) for synergy against clinical isolates of nosocomial strains of Pseudomonas aeruginosa, Stenotrophomonas maltophilia, and Burkholderia cepacia."( In vitro activity of ciprofloxacin, levofloxacin, and trovafloxacin, alone and in combination with beta-lactams, against clinical isolates of Pseudomonas aeruginosa, Stenotrophomonas maltophilia, and Burkholderia cepacia.
Alperstein, P; France, K; Isenberg, HD, 1999
)
0.79
"The killing activities of trovafloxacin alone and in combination with beta-lactam agents (extended-spectrum cephalosporins, meropenem), rifampin, or vancomycin were evaluated against 20 genotypically characterized Streptococcus pneumoniae isolates for which amoxicillin MICs were >/=4 microg/ml (cefotaxime MICs, >/=4 microg/ml for six strains) at concentrations clinically achievable in cerebrospinal fluid."( Killing activities of trovafloxacin alone and in combination with beta-lactam agents, rifampin, or vancomycin against Streptococcus pneumoniae isolates with various susceptibilities to extended-spectrum cephalosporins at concentrations clinically achievab
Bingen, E; Doit, C; Fitoussi, F; Geslin, P, 1999
)
0.92
"Although ciprofloxacin exhibits more intense microbiological activity against Pseudomonas aeruginosa than does trovafloxacin, the clinical relevance of this observation remains questionable, particularly when the agents are combined with another antipseudomonal agent."( Comparison of the bactericidal activity of trovafloxacin and ciprofloxacin, alone and in combination with cefepime, against Pseudomonas aeruginosa.
McNabb, J; Nicolau, DP; Nightingale, CH; Quintiliani, R,
)
0.61
" aeruginosa, when a fluoroquinolone is combined with a beta-lactam, this is likely to be of little clinical significance."( Comparison of the bactericidal activity of trovafloxacin and ciprofloxacin, alone and in combination with cefepime, against Pseudomonas aeruginosa.
McNabb, J; Nicolau, DP; Nightingale, CH; Quintiliani, R,
)
0.39
"To investigate the phamacokinetics and serum bactericidal activities (SBAs) of trovafloxacin, cefepime and amikacin alone and trovafloxacin in combination with cefepime or amikacin, so that the most favorable combination with trovafloxacin can be determined."( Serum bactericidal activity of trovafloxacin, in combination with cefepime or amikacin, in healthy volunteers.
Borner, K; Brodersen, B; Koeppe, P; Lode, H; Lubasch, A; Ziege, S, 2003
)
0.83
" However, the maximal concentration of cefepime was significantly lower when it was used in combination with trovafloxacin."( Serum bactericidal activity of trovafloxacin, in combination with cefepime or amikacin, in healthy volunteers.
Borner, K; Brodersen, B; Koeppe, P; Lode, H; Lubasch, A; Ziege, S, 2003
)
0.82
" aeruginosa, the bactericidal activity of cepefime alone was higher than that of the combination with trovafloxacin."( Serum bactericidal activity of trovafloxacin, in combination with cefepime or amikacin, in healthy volunteers.
Borner, K; Brodersen, B; Koeppe, P; Lode, H; Lubasch, A; Ziege, S, 2003
)
0.82

Bioavailability

Two studies determined the oral bioavailability of trovafloxacin (CP-99,219) in healthy volunteers under fasted and fed conditions. An open, placebo-controlled, randomized, four-way crossover study was conducted in 12 healthy male volunteers.

ExcerptReferenceRelevance
" The oral bioavailability of trovafloxacin was 68, 58, and 85% in rats, dogs, and monkeys, respectively."( Pharmacokinetics of trovafloxacin (CP-99,219), a new quinolone, in rats, dogs, and monkeys.
Foulds, G; Girard, D; Gootz, TD; Liston, TE; Teng, R, 1996
)
0.91
"Two studies determined the oral bioavailability of trovafloxacin (CP-99,219) in healthy volunteers under fasted and fed conditions."( Oral bioavailability of trovafloxacin with and without food in healthy volunteers.
Dogolo, LC; Friedman, HL; Teng, R; Vincent, J; Willavize, SA, 1997
)
0.86
"To determine the effect of the concurrent administration of Maalox and omeprazole in the bioavailability of trovafloxacin (CP-99,219), an open, placebo-controlled, randomized, four-way crossover study was conducted in 12 healthy male volunteers."( Effect of Maalox and omeprazole on the bioavailability of trovafloxacin.
Dogolo, LC; Friedman, HL; Teng, R; Vincent, J; Willavize, SA, 1997
)
0.75
" However, delivery of crushed oral formulations of drugs via nasogastric tubes is often carried out without adequate bioavailability data, and this method of administration may not always be equivalent to oral drug delivery."( The bioavailability of nasogastric versus tablet-form oral trovafloxacin in healthy subjects.
Friedman, HL; Pelletier, SM; Teng, R; Vincent, J; Willavize, SA, 1998
)
0.54
"Pharmacokinetic analyses showed that the bioavailability of trovafloxacin after administration of crushed tablets into the stomach with or without concomitant enteral feeding was not significantly different from that of the orally administered whole tablets: the 90% confidence limits of the area under the concentration-time curve (AUC(0-infinity)) for Treatment B versus Treatment A (91."( The bioavailability of nasogastric versus tablet-form oral trovafloxacin in healthy subjects.
Friedman, HL; Pelletier, SM; Teng, R; Vincent, J; Willavize, SA, 1998
)
0.79
"3%), indicating a 36% reduction in the bioavailability of trovafloxacin."( The pharmacokinetic effects of coadministration of morphine and trovafloxacin in healthy subjects.
Friedman, HL; Hunt, T; Robarge, L; Teng, R; Vincent, J; Willavize, SA, 1998
)
0.78
"Coadministration of trovafloxacin and morphine reduces the bioavailability and maximum serum concentrations of trovafloxacin."( The pharmacokinetic effects of coadministration of morphine and trovafloxacin in healthy subjects.
Friedman, HL; Hunt, T; Robarge, L; Teng, R; Vincent, J; Willavize, SA, 1998
)
0.86
" Excellent tissue pharmacokinetics and oral bioavailability suggest usefulness in the treatment of complicated intra-abdominal infections."( Trovafloxacin in the treatment of intra-abdominal infections: results of a double-blind, multicenter comparison with imipenem/cilastatin. Trovafloxacin Surgical Group.
Bur, F; Donahue, PE; Luke, DR; Mintz, SJ; Smith, DL; Yellin, AE, 1998
)
1.74
" The oral bioavailability under fasting conditions is approximately 88%."( Trovafloxacin: a new fluoroquinolone.
Alghasham, AA; Nahata, MC, 1999
)
1.75
" Its bioavailability is equivalent when administered either oral or intravenously."( [Pharmacokinetics of trovafloxacin: its clinical significance].
Biglia, MA; Clara, LO, 1999
)
0.62
" The mean absolute bioavailability was 91%."( Oral bioavailability and pharmacokinetics of trovafloxacin in patients with AIDS.
Geffken, A; Lacy, MK; Nicolau, DP; Nightingale, CH; Quintiliani, R; Teng, R; Vincent, J, 1999
)
0.56
"The following recommendations are made regarding intubation studies: (i) no intubation study is recommended for compounds with high permeability, since these compounds are likely to be well absorbed from the colon; (ii) compounds with moderate permeability may require an intubation study if the dog colon and in silico models predict a marginally acceptable CR concentration-time profile; (iii) use a dose that approximates 1 h of the intended CR delivery rate; (iv) use the smallest volume possible; (v) define and record tubing placement; (vi) use a thermodynamically stable solution or/and suspension."( The use of gastrointestinal intubation studies for controlled release development.
Sutton, SC, 2009
)
0.35
" These "in combo" PAMPA data were used to predict the human absolute bioavailability of the ampholytes."( The permeation of amphoteric drugs through artificial membranes--an in combo absorption model based on paracellular and transmembrane permeability.
Avdeef, A; Sun, N; Tam, KY; Tsinman, O, 2010
)
0.36
"Oral bioavailability (F) is a product of fraction absorbed (Fa), fraction escaping gut-wall elimination (Fg), and fraction escaping hepatic elimination (Fh)."( Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV, 2010
)
0.36
" The Loo-Riegelman and staircase deconvolution function methods were found to provide more reliable estimates of absorption rate than the Spath-spline and B-spline constraining break points deconvolution methods."( Using deconvolution to understand the mechanism for variable plasma concentration-time profiles after intramuscular injection.
Grice, JE; Liu, X; Mahmood, AH; Medley, GA; Roberts, MS, 2015
)
0.42

Dosage Studied

Trovafloxacin, at a dosage of 200 mg once or twice daily, should be adequate for the treatment of systemic infections.

ExcerptRelevanceReference
" Trovafloxacin was administered orally at 100 or 300 mg as a single dose followed by a 3 day washout period, and then was dosed once-daily for 14 consecutive days."( Multiple-dose pharmacokinetics and safety of trovafloxacin in healthy volunteers.
Harris, SC; Liston, TE; Teng, R, 1996
)
1.46
" Our results indicate that trovafloxacin, at a dosage of 200 mg once or twice daily, should be adequate for the treatment of systemic infections caused by most common bacterial pathogens."( Pharmacokinetics and penetration into inflammatory fluid of trovafloxacin (CP-99,219).
Andrews, JM; Child, J; Mortiboy, D; Wise, R, 1996
)
0.83
" Its pharmacokinetic properties in humans have been shown to be compatible with a once-daily dosing regimen."( The chemistry and biological profile of trovafloxacin.
Brighty, KE; Gootz, TD, 1997
)
0.56
" To elucidate whether these conflicts are real or apparent, several predictors of the AMEs of two pharmacokinetically different antibiotics, trovafloxacin (TRO) and ciprofloxacin (CIP), as well as different dosing regimens of CIP were examined."( Inter- and intraquinolone predictors of antimicrobial effect in an in vitro dynamic model: new insight into a widely used concept.
Firsov, AA; Shevchenko, AA; Vostrov, SN; Zinner, SH, 1998
)
0.5
"A simplified dosing algorithm for trovafloxacin was evaluated following a single-dose infusion of alatrofloxacin at trovafloxacin equivalent doses of 30, 100, 200, 300 and 400 mg (57 subjects), and multiple doses of 200, 300 and 400 mg (30 subjects)."( Single- and multiple-dose administration, dosing regimens, and pharmacokinetics of trovafloxacin and alatrofloxacin in humans.
Baris, BA; Dogolo, L; Teng, R; Vincent, J; Willavize, SA, 1998
)
0.8
" It is hepatically metabolized, and dosage adjustments are necessary for patients with severe hepatic dysfunction but not for those with mild or moderate dysfunction or renal dysfunction."( Trovafloxacin: an overview.
Amsden, GW; Garey, KW, 1999
)
1.75
" This dosing regimen is well tolerated."( Penetration of trovafloxacin into gynecologic tissues.
Maccato, M; Martens, MG; Van Hook, C; Vincent, J, 1998
)
0.65
"In an open-label, randomized, four-period, four-treatment, cross-over study, 24 healthy volunteers were given one dose of each of the following treatments, with a 7-day wash-out between dosing periods: Treatment A: two 100-mg trovafloxacin tablets given orally with 240 mL water; Treatment B: two crushed 100-mg trovafloxacin tablets suspended in water and administered through a nasogastric tube into the stomach; Treatment C: two crushed 100-mg trovafloxacin tablets suspended in water and administered through a nasogastric tube into the duodenum; or Treatment D: two crushed 100-mg trovafloxacin tablets suspended in water and given through a nasogastric tube into the stomach concomitantly with an enteral feeding solution (240 mL full-strength Osmolite)."( The bioavailability of nasogastric versus tablet-form oral trovafloxacin in healthy subjects.
Friedman, HL; Pelletier, SM; Teng, R; Vincent, J; Willavize, SA, 1998
)
0.73
"The advantages of once-daily dosing and enhanced activity of trovafloxacin against gram-positive and anaerobic organisms may expand its use over available fluoroquinolones."( Trovafloxacin: a new fluoroquinolone.
Alghasham, AA; Nahata, MC, 1999
)
1.99
"001) the differences between divided and single dosage regimens were not significant."( Pharmacodynamics of trovafloxacin in a mouse model of cephalosporin-resistant Streptococcus pneumoniae pneumonia.
Friedland, IR; Ghaffar, F; Jafri, H; Lutsar, I; McCracken, GH; Ng, W; Wubbel, L, 1999
)
0.63
"Four once-daily dosing regimens were used: 200 mg for 7 days, 200 mg for 5 days, 100 mg for 7 days, and 50 mg for 7 days."( A phase-II study of trovafloxacin for the treatment of Chlamydia trachomatis infections.
Johnson, RB; Jones, RB; Martin, DH, 1999
)
0.63
" Of 86 patients receiving the three highest dosing regimens, 17 (20%) had at least one adverse event, judged treatment-related in only 9 (10 %)."( A phase-II study of trovafloxacin for the treatment of Chlamydia trachomatis infections.
Johnson, RB; Jones, RB; Martin, DH, 1999
)
0.63
" Cost saving may be achieved with trovafloxacin due to the lack of any need to monitor creatinine levels and the once-daily dosing regimen that allows a switch to the same orally administered drug."( Treatment of complicated intra-abdominal infections: comparison of the tolerability and safety of intravenous/oral trovafloxacin versus intravenous imipenem/cilastatin switching to oral amoxycillin/clavulanic acid.
Luke, DR; Peterson, J,
)
0.62
" pneumoniae, with standard dosing resulting in area under the concentration-time curve/MIC ratios and peak concentration/MIC ratios that resulted in 99."( Activities of trovafloxacin, gatifloxacin, clinafloxacin, sparfloxacin, levofloxacin, and ciprofloxacin against penicillin-resistant Streptococcus pneumoniae in an in vitro infection model.
Hershberger, E; Rybak, MJ, 2000
)
0.67
" Dose-response experiments with two topoisomerase IV mutants that confer clinical resistance to quinolones (GrlA(Ser80Phe) and GrlA(Glu84Lys)) indicate that resistance is caused by a decrease in both drug affinity and efficacy."( Action of quinolones against Staphylococcus aureus topoisomerase IV: basis for DNA cleavage enhancement.
Anderson, VE; Gootz, TD; Kaczmarek, FS; Osheroff, N; Zaniewski, RP, 2000
)
0.31
"5 microg/ml) of common pediatric bacterial pathogens to trovafloxacin, dosing of 4 mg/kg/day once or twice daily should be appropriate."( Pharmacokinetics of a fluoronaphthyridone, trovafloxacin (CP 99,219), in infants and children following administration of a single intravenous dose of alatrofloxacin.
Bradley, JS; Capparelli, EV; Kearns, GL; Reed, MD; Vincent, J, 2000
)
0.82
" The concentrations of Trovafloxacin that inhibited HIV-1 replication are comparable to the plasma and tissue levels achieved by therapeutic dosage used in the treatment of bacterial infections."( Salmonella typhimurium-induced reactivation of latent HIV-1 in promonocytic U1 cells is inhibited by trovafloxacin.
Gollapudi, S; Gupta, S; Thadepalli, H, 2000
)
0.83
" Models were dosed the same as rabbit models, and SEVs were evaluated at the same time the rabbit vegetations were examined."( Comparison of a rabbit model of bacterial endocarditis and an in vitro infection model with simulated endocardial vegetations.
Coyle, EA; Hershberger, E; Kaatz, GW; Rybak, MJ; Zervos, MJ, 2000
)
0.31
" Gemifloxacin was found to be highly bactericidal against these bacteria, producing a biphasic dose-response curve typical of the fluoroquinolones."( The bactericidal activity of gemifloxacin (SB-265805).
Clark, S; Mathias, I; Morrissey, I, 2000
)
0.31
" Bactericidal activity of gatifloxacin was correlated with the area under the time-concentration curve-to-MBC ratio; maximal activity was achieved when gatifloxacin concentrations exceeded the MBC for the entire dosing interval."( Pharmacodynamics of gatifloxacin in experimental models of pneumococcal meningitis.
McCracken, GH, 2000
)
0.31
" Additionally, both combination regimens provided bactericidal activity for 100% of the dosing interval for all isolates."( Comparison of the bactericidal activity of trovafloxacin and ciprofloxacin, alone and in combination with cefepime, against Pseudomonas aeruginosa.
McNabb, J; Nicolau, DP; Nightingale, CH; Quintiliani, R,
)
0.39
" Dosing regimens were chosen to obtain a comparable area under the concentration-time curve from 0 to infinity/MIC ratio of 27."( Differential selection of multidrug efflux mutants by trovafloxacin and ciprofloxacin in an experimental model of Pseudomonas aeruginosa acute pneumonia in rats.
Carbon, C; Chau, F; Dautrey, S; Faurisson, F; Join-Lambert, OF; Köhler, T; Michéa-Hamzehpour, M; Pechère, J; Vissuzaine, C, 2001
)
0.56
" Daily dosing regimens of 37."( In vivo efficacy of trovafloxacin against Bacteroides fragilis in mixed infection with either Escherichia coli or a vancomycin-resistant strain of Enterococcus faecium in an established-abscess murine model.
Goessens, WH; Gyssens, IC; Mouton, JW; Oyen, WJ; Stearne, LE; van der Meer, JW; Verbrugh, HA, 2001
)
0.63
" One hundred and nineteen animals were treated with one of the following antibiotic regimens: im procaine penicillin G at a dosage of 300,000 U/kg weight/12 h (16 animals); iv trovafloxacin, 13."( Comparative study of treatment with penicillin, ceftriaxone, trovafloxacin, quinupristin-dalfopristin and vancomycin in experimental endocarditis due to penicillin- and ceftriaxone-resistant Streptococcus pneumoniae.
Cortés Sanchez, R; García Alberola, A; Gómez Gómez, J; López Fornas, F; Martínez García, F; Pérez Salmeron, J; Roldán Conesa, D; Ruíz Gómez, J; Valdés Chávarri, M, 2001
)
0.75
" All quinolones tested selected for resistance; judicious use and proper dosing will be necessary to avoid resistance selection of newer broad-spectrum fluoroquinolones."( Single- and multi-step resistance selection study of gemifloxacin compared with trovafloxacin, ciprofloxacin, gatifloxacin and moxifloxacin in Streptococcus pneumoniae.
Appelbaum, PC; Davies, TA; Dewasse, BE; Jacobs, MR; Nagai, K, 2001
)
0.54
" Trovafloxacin serum bactericidal titres against the ciprofloxacin-resistant strain were measurable generally only at 1 h after dosing (median titre=2)."( Influence of diminished susceptibility of Streptococcus pneumoniae to ciprofloxacin on the serum bactericidal activity of gemifloxacin and trovafloxacin after a single dose in healthy volunteers.
Aguilar, L; Alou, L; Dal-Ré, R; Frías, J; Fuentes, F; Giménez, MJ; Prieto, J; Sörgel, F, 2001
)
1.42
" This study suggests that both bacterial strain-independent AUC/MIC- and the respective strain-specific dose-response relationships of the AME are important for comprehensive pharmacodynamic evaluation of antimicrobial agents."( Bacterial strain-independent AUC/MIC and strain-specific dose-response relationships reflecting comparative fluoroquinolone anti-pseudomonal pharmacodynamics in an in vitro dynamic model.
Firsov, AA; Lubenko, IY; Portnoy, YA; Vostrov, SN; Zinner, SH, 2002
)
0.31
" Also included are human pharmacokinetic studies with prototype CR dosage forms for CJ-13,610 and CP-424,391."( The use of gastrointestinal intubation studies for controlled release development.
Sutton, SC, 2009
)
0.35
" We proposed a systematic classification scheme using FDA-approved drug labeling to assess the DILI potential of drugs, which yielded a benchmark dataset with 287 drugs representing a wide range of therapeutic categories and daily dosage amounts."( FDA-approved drug labeling for the study of drug-induced liver injury.
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V, 2011
)
0.37
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Thromboxane-A synthase Homo sapiens (human)IC50 (µMol)4.02300.00091.230410.0000AID625229
Sodium-dependent dopamine transporter Homo sapiens (human)IC50 (µMol)62.19100.00071.841946.0000AID625256
Sodium-dependent dopamine transporter Homo sapiens (human)Ki49.41200.00021.11158.0280AID625256
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (32)

Processvia Protein(s)Taxonomy
prostaglandin biosynthetic processThromboxane-A synthase Homo sapiens (human)
icosanoid metabolic processThromboxane-A synthase Homo sapiens (human)
cyclooxygenase pathwayThromboxane-A synthase Homo sapiens (human)
intracellular chloride ion homeostasisThromboxane-A synthase Homo sapiens (human)
response to ethanolThromboxane-A synthase Homo sapiens (human)
positive regulation of vasoconstrictionThromboxane-A synthase Homo sapiens (human)
response to fatty acidThromboxane-A synthase Homo sapiens (human)
monoamine transportSodium-dependent dopamine transporter Homo sapiens (human)
neurotransmitter transportSodium-dependent dopamine transporter Homo sapiens (human)
lactationSodium-dependent dopamine transporter Homo sapiens (human)
sensory perception of smellSodium-dependent dopamine transporter Homo sapiens (human)
locomotory behaviorSodium-dependent dopamine transporter Homo sapiens (human)
response to xenobiotic stimulusSodium-dependent dopamine transporter Homo sapiens (human)
response to iron ionSodium-dependent dopamine transporter Homo sapiens (human)
dopamine transportSodium-dependent dopamine transporter Homo sapiens (human)
adenohypophysis developmentSodium-dependent dopamine transporter Homo sapiens (human)
response to nicotineSodium-dependent dopamine transporter Homo sapiens (human)
positive regulation of multicellular organism growthSodium-dependent dopamine transporter Homo sapiens (human)
regulation of dopamine metabolic processSodium-dependent dopamine transporter Homo sapiens (human)
response to cocaineSodium-dependent dopamine transporter Homo sapiens (human)
dopamine biosynthetic processSodium-dependent dopamine transporter Homo sapiens (human)
dopamine catabolic processSodium-dependent dopamine transporter Homo sapiens (human)
response to ethanolSodium-dependent dopamine transporter Homo sapiens (human)
cognitionSodium-dependent dopamine transporter Homo sapiens (human)
dopamine uptake involved in synaptic transmissionSodium-dependent dopamine transporter Homo sapiens (human)
response to cAMPSodium-dependent dopamine transporter Homo sapiens (human)
norepinephrine uptakeSodium-dependent dopamine transporter Homo sapiens (human)
prepulse inhibitionSodium-dependent dopamine transporter Homo sapiens (human)
dopamine uptakeSodium-dependent dopamine transporter Homo sapiens (human)
hyaloid vascular plexus regressionSodium-dependent dopamine transporter Homo sapiens (human)
amino acid transportSodium-dependent dopamine transporter Homo sapiens (human)
norepinephrine transportSodium-dependent dopamine transporter Homo sapiens (human)
sodium ion transmembrane transportSodium-dependent dopamine transporter Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (20)

Processvia Protein(s)Taxonomy
monooxygenase activityThromboxane-A synthase Homo sapiens (human)
thromboxane-A synthase activityThromboxane-A synthase Homo sapiens (human)
iron ion bindingThromboxane-A synthase Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygenThromboxane-A synthase Homo sapiens (human)
heme bindingThromboxane-A synthase Homo sapiens (human)
12-hydroxyheptadecatrienoic acid synthase activityThromboxane-A synthase Homo sapiens (human)
hydroperoxy icosatetraenoate dehydratase activityThromboxane-A synthase Homo sapiens (human)
protease bindingSodium-dependent dopamine transporter Homo sapiens (human)
signaling receptor bindingSodium-dependent dopamine transporter Homo sapiens (human)
neurotransmitter transmembrane transporter activitySodium-dependent dopamine transporter Homo sapiens (human)
dopamine:sodium symporter activitySodium-dependent dopamine transporter Homo sapiens (human)
protein bindingSodium-dependent dopamine transporter Homo sapiens (human)
monoamine transmembrane transporter activitySodium-dependent dopamine transporter Homo sapiens (human)
dopamine bindingSodium-dependent dopamine transporter Homo sapiens (human)
amine bindingSodium-dependent dopamine transporter Homo sapiens (human)
protein-containing complex bindingSodium-dependent dopamine transporter Homo sapiens (human)
metal ion bindingSodium-dependent dopamine transporter Homo sapiens (human)
protein phosphatase 2A bindingSodium-dependent dopamine transporter Homo sapiens (human)
heterocyclic compound bindingSodium-dependent dopamine transporter Homo sapiens (human)
norepinephrine:sodium symporter activitySodium-dependent dopamine transporter Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (17)

Processvia Protein(s)Taxonomy
endoplasmic reticulumThromboxane-A synthase Homo sapiens (human)
endoplasmic reticulum membraneThromboxane-A synthase Homo sapiens (human)
cytosolThromboxane-A synthase Homo sapiens (human)
cytoplasmSodium-dependent dopamine transporter Homo sapiens (human)
plasma membraneSodium-dependent dopamine transporter Homo sapiens (human)
cell surfaceSodium-dependent dopamine transporter Homo sapiens (human)
membraneSodium-dependent dopamine transporter Homo sapiens (human)
axonSodium-dependent dopamine transporter Homo sapiens (human)
neuron projectionSodium-dependent dopamine transporter Homo sapiens (human)
neuronal cell bodySodium-dependent dopamine transporter Homo sapiens (human)
axon terminusSodium-dependent dopamine transporter Homo sapiens (human)
membrane raftSodium-dependent dopamine transporter Homo sapiens (human)
postsynaptic membraneSodium-dependent dopamine transporter Homo sapiens (human)
dopaminergic synapseSodium-dependent dopamine transporter Homo sapiens (human)
flotillin complexSodium-dependent dopamine transporter Homo sapiens (human)
axonSodium-dependent dopamine transporter Homo sapiens (human)
presynaptic membraneSodium-dependent dopamine transporter Homo sapiens (human)
plasma membraneSodium-dependent dopamine transporter Homo sapiens (human)
neuronal cell body membraneSodium-dependent dopamine transporter Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (216)

Assay IDTitleYearJournalArticle
AID475010Antibacterial activity against Haemophilus influenzae LCB0015 by two fold serial dilution method2010Bioorganic & medicinal chemistry letters, Apr-01, Volume: 20, Issue:7
Synthesis, crystal and antibacterial studies of diversely functionalized tetrahydropyridin-4-ol.
AID1430299Antibacterial activity against Staphylococcus aureus ATCC 25923 assessed as decrease in ATP level at 1.95 ug/ml after 24 hrs by BacTiter-Glo reagent based bioluminescence assay2017Bioorganic & medicinal chemistry letters, 03-01, Volume: 27, Issue:5
New 1,4-dihydro[1,8]naphthyridine derivatives as DNA gyrase inhibitors.
AID425653Renal clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID1557287Antibacterial activity against Enterococcus by agar diffusion method2019MedChemComm, Oct-01, Volume: 10, Issue:10
Quinolone antibiotics.
AID559558Antimicrobial activity against compound-susceptible Coxiella burnetii isolate CP6 obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics.
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID410223Antibacterial activity against Klebsiella pneumoniae by broth micro dilution method2008Bioorganic & medicinal chemistry letters, Dec-15, Volume: 18, Issue:24
A facile synthesis, antibacterial, and antitubercular studies of some piperidin-4-one and tetrahydropyridine derivatives.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID588210Human drug-induced liver injury (DILI) modelling dataset from Ekins et al2010Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 38, Issue:12
A predictive ligand-based Bayesian model for human drug-induced liver injury.
AID1557285Antibacterial activity against Streptococcus pneumoniae by agar diffusion method2019MedChemComm, Oct-01, Volume: 10, Issue:10
Quinolone antibiotics.
AID1557286Antibacterial activity against Streptococcus pyogenes by agar diffusion method2019MedChemComm, Oct-01, Volume: 10, Issue:10
Quinolone antibiotics.
AID1557325Toxicity in human assessed as CNS effect by measuring dizziness2019MedChemComm, Oct-01, Volume: 10, Issue:10
Quinolone antibiotics.
AID540232Dose normalised AUC in monkey after po administration2005Xenobiotica; the fate of foreign compounds in biological systems, Feb, Volume: 35, Issue:2
Comparative evaluation of oral systemic exposure of 56 xenobiotics in rat, dog, monkey and human.
AID1557284Antibacterial activity against Staphylococcus aureus by agar diffusion method2019MedChemComm, Oct-01, Volume: 10, Issue:10
Quinolone antibiotics.
AID475006Antibacterial activity against Escherichia coli LCB0011 by two fold serial dilution method2010Bioorganic & medicinal chemistry letters, Apr-01, Volume: 20, Issue:7
Synthesis, crystal and antibacterial studies of diversely functionalized tetrahydropyridin-4-ol.
AID559563Antimicrobial activity against compound-intermediate susceptible Coxiella burnetii isolate CP8 obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics.
AID540217Volume of distribution at steady state in dog after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID456032Antibacterial activity against Escherichia coli NIHJ after 18 hrs by twofold microbroth dilution method2009Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19
Design, synthesis and biological evaluations of novel 7-[3-(1-aminocycloalkyl)pyrrolidin-1-yl]-6-desfluoro-8-methoxyquinolones with potent antibacterial activity against multi-drug resistant Gram-positive bacteria.
AID781326pKa (acid-base dissociation constant) as determined by Avdeef ref: DOI: 10.1002/047145026X2014Pharmaceutical research, Apr, Volume: 31, Issue:4
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
AID540221Volume of distribution at steady state in human after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID559560Antimicrobial activity against compound-intermediate susceptible Coxiella burnetii isolate CP7 obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID559557Antimicrobial activity against compound-intermediate susceptible Coxiella burnetii isolate CP6 obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics.
AID410203Antibacterial activity against Staphylococcus epidermidis by broth micro dilution method2008Bioorganic & medicinal chemistry letters, Dec-15, Volume: 18, Issue:24
A facile synthesis, antibacterial, and antitubercular studies of some piperidin-4-one and tetrahydropyridine derivatives.
AID1557319Cmax in human at 0.3 g, po2019MedChemComm, Oct-01, Volume: 10, Issue:10
Quinolone antibiotics.
AID559366Antimicrobial activity against compound-susceptible Coxiella burnetii isolate CP1 obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics.
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID475004Antibacterial activity against Enterococcus faecium LCB0009 by two fold serial dilution method2010Bioorganic & medicinal chemistry letters, Apr-01, Volume: 20, Issue:7
Synthesis, crystal and antibacterial studies of diversely functionalized tetrahydropyridin-4-ol.
AID496824Antimicrobial activity against Toxoplasma gondii2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1888652Antibacterial activity against Escherichia coli assessed as inhibition of bacterial growth2022Bioorganic & medicinal chemistry letters, 02-01, Volume: 57Synthesis and evaluation of dual-action kanglemycin-fluoroquinolone hybrid antibiotics.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID1430296Antibacterial activity against Enterococcus faecalis ATCC 51299 incubated after 24 hrs by resazurin dye based broth microdilution assay2017Bioorganic & medicinal chemistry letters, 03-01, Volume: 27, Issue:5
New 1,4-dihydro[1,8]naphthyridine derivatives as DNA gyrase inhibitors.
AID86394Cytotoxicity was determined for the compound in HepG2 cell line2004Bioorganic & medicinal chemistry letters, Mar-08, Volume: 14, Issue:5
Syntheses and biological evaluation of new fluoroquinolone antibacterials containing chiral oxiimino pyrrolidine.
AID540219Volume of distribution at steady state in monkey after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID237458Partition coefficient (logD7.4)2005Journal of medicinal chemistry, Aug-11, Volume: 48, Issue:16
A chiral benzoquinolizine-2-carboxylic acid arginine salt active against vancomycin-resistant Staphylococcus aureus.
AID237039Dissociation constant (pKa) was determined2005Journal of medicinal chemistry, Aug-11, Volume: 48, Issue:16
A chiral benzoquinolizine-2-carboxylic acid arginine salt active against vancomycin-resistant Staphylococcus aureus.
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID475002Antibacterial activity against vancomycin and Linezolid resistant Enterococcus faecalis LCB0007 by two fold serial dilution method2010Bioorganic & medicinal chemistry letters, Apr-01, Volume: 20, Issue:7
Synthesis, crystal and antibacterial studies of diversely functionalized tetrahydropyridin-4-ol.
AID521101Antimicrobial activity against Streptococcus sp. 'group B' isolate 16 harboring gyrA Ser81Leu mutant, parC Ser79Tyr mutant and parE Ileu495Leu mutant gene by agar dilution method2008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
Emergence of fluoroquinolone resistance in group B streptococcal isolates in Taiwan.
AID237034Dissociation constant (pKa) was determined2005Journal of medicinal chemistry, Aug-11, Volume: 48, Issue:16
A chiral benzoquinolizine-2-carboxylic acid arginine salt active against vancomycin-resistant Staphylococcus aureus.
AID559555Antimicrobial activity against compound-susceptible Coxiella burnetii isolate CP5 obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics.
AID410224Antibacterial activity against Haemophilus influenzae by broth micro dilution method2008Bioorganic & medicinal chemistry letters, Dec-15, Volume: 18, Issue:24
A facile synthesis, antibacterial, and antitubercular studies of some piperidin-4-one and tetrahydropyridine derivatives.
AID96072Antibacterial activity was determined against Klebsiella pneumoniae type II strain after incubation at 37 degrees C for 18 h2003Journal of medicinal chemistry, Mar-13, Volume: 46, Issue:6
Synthesis and structure-activity relationships of 5-amino-6-fluoro-1-[(1R,2S)-2-fluorocyclopropan-1-yl]-8-methylquinolonecarboxylic acid antibacterials having fluorinated 7-[(3R)-3-(1-aminocyclopropan-1-yl)pyrrolidin-1-yl] substituents.
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID436996Inhibition of mouse MC3T3-E1 cell proliferation after 48 to 72 hrs2009Bioorganic & medicinal chemistry, Aug-01, Volume: 17, Issue:15
7-((4-Substituted)piperazin-1-yl) derivatives of ciprofloxacin: synthesis and in vitro biological evaluation as potential antitumor agents.
AID209273Antibacterial activity was determined against Streptococcus pyogenes G-36 strain after incubation at 37 degrees C for 18 h2003Journal of medicinal chemistry, Mar-13, Volume: 46, Issue:6
Synthesis and structure-activity relationships of 5-amino-6-fluoro-1-[(1R,2S)-2-fluorocyclopropan-1-yl]-8-methylquinolonecarboxylic acid antibacterials having fluorinated 7-[(3R)-3-(1-aminocyclopropan-1-yl)pyrrolidin-1-yl] substituents.
AID410222Antibacterial activity against Pseudomonas aeruginosa by broth micro dilution method2008Bioorganic & medicinal chemistry letters, Dec-15, Volume: 18, Issue:24
A facile synthesis, antibacterial, and antitubercular studies of some piperidin-4-one and tetrahydropyridine derivatives.
AID559552Antimicrobial activity against compound-susceptible Coxiella burnetii isolate CP4 obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics.
AID67578Inhibitory activity against strain of E. faecalis; Range is 0.25-2 ug/mL1996Journal of medicinal chemistry, Sep-27, Volume: 39, Issue:20
New directions in antibacterial research.
AID559358Antimicrobial activity against compound-resistant Coxiella burnetii Nine-Mile obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics.
AID1430297Antibacterial activity against Listeria monocytogenes ATCC 7644 incubated after 24 hrs by resazurin dye based broth microdilution assay2017Bioorganic & medicinal chemistry letters, 03-01, Volume: 27, Issue:5
New 1,4-dihydro[1,8]naphthyridine derivatives as DNA gyrase inhibitors.
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1890607Induction of drug resistance in methicillin resistant Staphylococcus aureus assessed as increase in MIC measured after 10 passages (Rvb = 0.4 ug/ml)2022Bioorganic & medicinal chemistry letters, 05-01, Volume: 63WCK 1152, WCK 1153: Discovery and structure activity relationship for the treatment of resistant pneumococcal and staphylococcal respiratory infections.
AID559371Antimicrobial activity against compound-intermediate susceptible Coxiella burnetii isolate CP3 obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics.
AID1557280Antibacterial activity against Pseudomonas aeruginosa by agar diffusion method2019MedChemComm, Oct-01, Volume: 10, Issue:10
Quinolone antibiotics.
AID625276FDA Liver Toxicity Knowledge Base Benchmark Dataset (LTKB-BD) drugs of most concern for DILI2011Drug discovery today, Aug, Volume: 16, Issue:15-16
FDA-approved drug labeling for the study of drug-induced liver injury.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID69933Antibacterial activity was determined against Escherichia coli NIHJ strain after incubation at 37 degrees C for 18 h2003Journal of medicinal chemistry, Mar-13, Volume: 46, Issue:6
Synthesis and structure-activity relationships of 5-amino-6-fluoro-1-[(1R,2S)-2-fluorocyclopropan-1-yl]-8-methylquinolonecarboxylic acid antibacterials having fluorinated 7-[(3R)-3-(1-aminocyclopropan-1-yl)pyrrolidin-1-yl] substituents.
AID1430291Antibacterial activity against Staphylococcus aureus ATCC 25923 incubated after 24 hrs by resazurin dye based broth microdilution assay2017Bioorganic & medicinal chemistry letters, 03-01, Volume: 27, Issue:5
New 1,4-dihydro[1,8]naphthyridine derivatives as DNA gyrase inhibitors.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID559364Antimicrobial activity against compound-resistant Coxiella burnetii isolate CP1 obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics.
AID444054Oral bioavailability in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1430301Antibacterial activity against Escherichia coli ATCC 25922 assessed as decrease in ATP level at 1.95 ug/ml after 24 hrs by BacTiter-Glo reagent based bioluminescence assay2017Bioorganic & medicinal chemistry letters, 03-01, Volume: 27, Issue:5
New 1,4-dihydro[1,8]naphthyridine derivatives as DNA gyrase inhibitors.
AID410201Antibacterial activity against Staphylococcus aureus by broth micro dilution method2008Bioorganic & medicinal chemistry letters, Dec-15, Volume: 18, Issue:24
A facile synthesis, antibacterial, and antitubercular studies of some piperidin-4-one and tetrahydropyridine derivatives.
AID475011Antibacterial activity against Moraxella catarrhalis LCB0016 by two fold serial dilution method2010Bioorganic & medicinal chemistry letters, Apr-01, Volume: 20, Issue:7
Synthesis, crystal and antibacterial studies of diversely functionalized tetrahydropyridin-4-ol.
AID475000Antibacterial activity against Enterococcus faecalis LCB0005 by two fold serial dilution method2010Bioorganic & medicinal chemistry letters, Apr-01, Volume: 20, Issue:7
Synthesis, crystal and antibacterial studies of diversely functionalized tetrahydropyridin-4-ol.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID65236Tested for in vitro antibacterial activity against Escherichia coli W95232003Journal of medicinal chemistry, May-08, Volume: 46, Issue:10
A novel antibacterial 8-chloroquinolone with a distorted orientation of the N1-(5-amino-2,4-difluorophenyl) group.
AID74699In vitro antibacterial activity against Gram (-) bacteria2003Journal of medicinal chemistry, May-08, Volume: 46, Issue:10
A novel antibacterial 8-chloroquinolone with a distorted orientation of the N1-(5-amino-2,4-difluorophenyl) group.
AID1636357Drug activation in human Hep3B cells assessed as human CYP3A4-mediated drug metabolism-induced cytotoxicity measured as decrease in cell viability at 300 uM pre-incubated with BSO for 18 hrs followed by incubation with compound for 3 hrs in presence of NA2016Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
AID217047Cytotoxicity was determined for the compound in V79-4 cell line2004Bioorganic & medicinal chemistry letters, Mar-08, Volume: 14, Issue:5
Syntheses and biological evaluation of new fluoroquinolone antibacterials containing chiral oxiimino pyrrolidine.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID237457Partition coefficient (logD2.0)2005Journal of medicinal chemistry, Aug-11, Volume: 48, Issue:16
A chiral benzoquinolizine-2-carboxylic acid arginine salt active against vancomycin-resistant Staphylococcus aureus.
AID444050Fraction unbound in human plasma2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID475005Antibacterial activity against Escherichia coli LCB0010 by two fold serial dilution method2010Bioorganic & medicinal chemistry letters, Apr-01, Volume: 20, Issue:7
Synthesis, crystal and antibacterial studies of diversely functionalized tetrahydropyridin-4-ol.
AID1918193Dissociation constant, pKa of the compound2022Journal of medicinal chemistry, 11-10, Volume: 65, Issue:21
Identification of Organic Anion Transporter 2 Inhibitors: Screening, Structure-Based Analysis, and Clinical Drug Interaction Risk Assessment.
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID475001Antibacterial activity against vancomycin-resistant Enterococcus faecalis LCB0006 by two fold serial dilution method2010Bioorganic & medicinal chemistry letters, Apr-01, Volume: 20, Issue:7
Synthesis, crystal and antibacterial studies of diversely functionalized tetrahydropyridin-4-ol.
AID540230Dose normalised AUC in rat after po administration2005Xenobiotica; the fate of foreign compounds in biological systems, Feb, Volume: 35, Issue:2
Comparative evaluation of oral systemic exposure of 56 xenobiotics in rat, dog, monkey and human.
AID559370Antimicrobial activity against compound-resistant Coxiella burnetii isolate CP3 obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics.
AID445445Permeability at pH 6.5 by PAMPA method2010Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1
The permeation of amphoteric drugs through artificial membranes--an in combo absorption model based on paracellular and transmembrane permeability.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID1888650Antibacterial activity against ciprofloxacin resistant Staphylococcus aureus harboring ParCS80F and GyrAS84L double mutant assessed as inhibition of bacterial growth2022Bioorganic & medicinal chemistry letters, 02-01, Volume: 57Synthesis and evaluation of dual-action kanglemycin-fluoroquinolone hybrid antibiotics.
AID559564Antimicrobial activity against compound-susceptible Coxiella burnetii isolate CP8 obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics.
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID559365Antimicrobial activity against compound-intermediate susceptible Coxiella burnetii isolate CP1 obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics.
AID559550Antimicrobial activity against compound-resistant Coxiella burnetii isolate CP4 obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics.
AID474998Antibacterial activity against Staphylococcus epidermidis LCB0003 by two fold serial dilution method2010Bioorganic & medicinal chemistry letters, Apr-01, Volume: 20, Issue:7
Synthesis, crystal and antibacterial studies of diversely functionalized tetrahydropyridin-4-ol.
AID410221Antibacterial activity against Escherichia coli LCB0012 by broth micro dilution method2008Bioorganic & medicinal chemistry letters, Dec-15, Volume: 18, Issue:24
A facile synthesis, antibacterial, and antitubercular studies of some piperidin-4-one and tetrahydropyridine derivatives.
AID559561Antimicrobial activity against compound-susceptible Coxiella burnetii isolate CP7 obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics.
AID208148Inhibitory activity against S. pneumoniae; Range is 0.12-0.25 ug/mL1996Journal of medicinal chemistry, Sep-27, Volume: 39, Issue:20
New directions in antibacterial research.
AID540233Dose normalised AUC in human after po administration2005Xenobiotica; the fate of foreign compounds in biological systems, Feb, Volume: 35, Issue:2
Comparative evaluation of oral systemic exposure of 56 xenobiotics in rat, dog, monkey and human.
AID207483Antibacterial activity was determined against Staphylococcus aureus FDA 209-P strain after incubation at 37 degrees C for 18 h2003Journal of medicinal chemistry, Mar-13, Volume: 46, Issue:6
Synthesis and structure-activity relationships of 5-amino-6-fluoro-1-[(1R,2S)-2-fluorocyclopropan-1-yl]-8-methylquinolonecarboxylic acid antibacterials having fluorinated 7-[(3R)-3-(1-aminocyclopropan-1-yl)pyrrolidin-1-yl] substituents.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID559367Antimicrobial activity against compound-resistant Coxiella burnetii isolate CP2 obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics.
AID159909In vitro inhibitory activity against hepatic stages of Plasmodium yoelii yoelii 265 BY2004Bioorganic & medicinal chemistry letters, Jun-07, Volume: 14, Issue:11
Synthesis of new fluoroquinolones and evaluation of their in vitro activity on Toxoplasma gondii and Plasmodium spp.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID1430303Cytotoxicity against mouse NIH/3T3 cells assessed as reduction in cell proliferation after 24 hrs by MTT assay2017Bioorganic & medicinal chemistry letters, 03-01, Volume: 27, Issue:5
New 1,4-dihydro[1,8]naphthyridine derivatives as DNA gyrase inhibitors.
AID410225Antibacterial activity against Moraxella catarrhalis by broth micro dilution method2008Bioorganic & medicinal chemistry letters, Dec-15, Volume: 18, Issue:24
A facile synthesis, antibacterial, and antitubercular studies of some piperidin-4-one and tetrahydropyridine derivatives.
AID1888651Antibacterial activity against Staphylococcus aureus harboring RpoBH481Y/ParCS80F/GyrAS84L triple mutant assessed as inhibition of bacterial growth2022Bioorganic & medicinal chemistry letters, 02-01, Volume: 57Synthesis and evaluation of dual-action kanglemycin-fluoroquinolone hybrid antibiotics.
AID209591Antibacterial activity was determined against Streptococcus mitis IID685 strain after incubation at 37 degrees C for 18 h2003Journal of medicinal chemistry, Mar-13, Volume: 46, Issue:6
Synthesis and structure-activity relationships of 5-amino-6-fluoro-1-[(1R,2S)-2-fluorocyclopropan-1-yl]-8-methylquinolonecarboxylic acid antibacterials having fluorinated 7-[(3R)-3-(1-aminocyclopropan-1-yl)pyrrolidin-1-yl] substituents.
AID444058Volume of distribution at steady state in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID445446Oral bioavailability in human2010Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1
The permeation of amphoteric drugs through artificial membranes--an in combo absorption model based on paracellular and transmembrane permeability.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID475008Antibacterial activity against Pseudomonas aeruginosa LCB0013 by two fold serial dilution method2010Bioorganic & medicinal chemistry letters, Apr-01, Volume: 20, Issue:7
Synthesis, crystal and antibacterial studies of diversely functionalized tetrahydropyridin-4-ol.
AID559553Antimicrobial activity against compound-resistant Coxiella burnetii isolate CP5 obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics.
AID540216Clearance in dog after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID559359Antimicrobial activity against compound-intermediate susceptible Coxiella burnetii Nine-Mile obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics.
AID106707Tested for in vitro antibacterial activity against methicillin resistant Staphylococcus aureus W95012003Journal of medicinal chemistry, May-08, Volume: 46, Issue:10
A novel antibacterial 8-chloroquinolone with a distorted orientation of the N1-(5-amino-2,4-difluorophenyl) group.
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID158681In vitro inhibitory activity against chloroquine-resistant Plasmodium falciparum NF54-R in blood2004Bioorganic & medicinal chemistry letters, Jun-07, Volume: 14, Issue:11
Synthesis of new fluoroquinolones and evaluation of their in vitro activity on Toxoplasma gondii and Plasmodium spp.
AID210029Antibacterial activity was determined against Streptococcus pneumoniae J-24 strain after incubation at 37 degrees C for 18 h2003Journal of medicinal chemistry, Mar-13, Volume: 46, Issue:6
Synthesis and structure-activity relationships of 5-amino-6-fluoro-1-[(1R,2S)-2-fluorocyclopropan-1-yl]-8-methylquinolonecarboxylic acid antibacterials having fluorinated 7-[(3R)-3-(1-aminocyclopropan-1-yl)pyrrolidin-1-yl] substituents.
AID559554Antimicrobial activity against compound-intermediate susceptible Coxiella burnetii isolate CP5 obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1430295Antibacterial activity against Enterococcus faecalis ATCC 29212 incubated after 24 hrs by resazurin dye based broth microdilution assay2017Bioorganic & medicinal chemistry letters, 03-01, Volume: 27, Issue:5
New 1,4-dihydro[1,8]naphthyridine derivatives as DNA gyrase inhibitors.
AID1557320AUC in human at 0.3 g, po2019MedChemComm, Oct-01, Volume: 10, Issue:10
Quinolone antibiotics.
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID456026Antibacterial activity against Staphylococcus aureus FDA 209-P after 18 hrs by twofold microbroth dilution method2009Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19
Design, synthesis and biological evaluations of novel 7-[3-(1-aminocycloalkyl)pyrrolidin-1-yl]-6-desfluoro-8-methoxyquinolones with potent antibacterial activity against multi-drug resistant Gram-positive bacteria.
AID1557279Antibacterial activity against Escherichia coli by agar diffusion method2019MedChemComm, Oct-01, Volume: 10, Issue:10
Quinolone antibiotics.
AID456028Antibacterial activity against Streptococcus pneumoniae J-24 after 18 hrs by twofold microbroth dilution method2009Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19
Design, synthesis and biological evaluations of novel 7-[3-(1-aminocycloalkyl)pyrrolidin-1-yl]-6-desfluoro-8-methoxyquinolones with potent antibacterial activity against multi-drug resistant Gram-positive bacteria.
AID540215Volume of distribution at steady state in rat after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID474997Antibacterial activity against methicillin-resistant Staphylococcus aureus LCB0002 by two fold serial dilution method2010Bioorganic & medicinal chemistry letters, Apr-01, Volume: 20, Issue:7
Synthesis, crystal and antibacterial studies of diversely functionalized tetrahydropyridin-4-ol.
AID1636457Drug activation in human Hep3B cells assessed as human CYP2D6-mediated drug metabolism-induced cytotoxicity measured as decrease in cell viability at 264.7 uM pre-incubated with BSO for 18 hrs followed by incubation with compound for 3 hrs in presence of 2016Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
AID151671Tested for in vitro antibacterial activity against Pseudomonas aeruginosa W3482003Journal of medicinal chemistry, May-08, Volume: 46, Issue:10
A novel antibacterial 8-chloroquinolone with a distorted orientation of the N1-(5-amino-2,4-difluorophenyl) group.
AID559369Antimicrobial activity against compound-susceptible Coxiella burnetii isolate CP2 obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics.
AID559562Antimicrobial activity against compound-resistant Coxiella burnetii isolate CP8 obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics.
AID456031Antibacterial activity against Enterococcus faecalis ATCC 19433 after 18 hrs by twofold microbroth dilution method2009Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19
Design, synthesis and biological evaluations of novel 7-[3-(1-aminocycloalkyl)pyrrolidin-1-yl]-6-desfluoro-8-methoxyquinolones with potent antibacterial activity against multi-drug resistant Gram-positive bacteria.
AID1430298Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 incubated after 24 hrs by resazurin dye based broth microdilution assay2017Bioorganic & medicinal chemistry letters, 03-01, Volume: 27, Issue:5
New 1,4-dihydro[1,8]naphthyridine derivatives as DNA gyrase inhibitors.
AID559361Antimicrobial activity against compound-resistant Coxiella burnetii Q212 obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics.
AID1430294Antibacterial activity against Klebsiella pneumoniae ATCC 700603 incubated after 24 hrs by resazurin dye based broth microdilution assay2017Bioorganic & medicinal chemistry letters, 03-01, Volume: 27, Issue:5
New 1,4-dihydro[1,8]naphthyridine derivatives as DNA gyrase inhibitors.
AID1430293Antibacterial activity against Escherichia coli ATCC 25922 incubated after 24 hrs by resazurin dye based broth microdilution assay2017Bioorganic & medicinal chemistry letters, 03-01, Volume: 27, Issue:5
New 1,4-dihydro[1,8]naphthyridine derivatives as DNA gyrase inhibitors.
AID410206Antibacterial activity against vancomycin-resistant Enterococcus faecalis by broth micro dilution method2008Bioorganic & medicinal chemistry letters, Dec-15, Volume: 18, Issue:24
A facile synthesis, antibacterial, and antitubercular studies of some piperidin-4-one and tetrahydropyridine derivatives.
AID444051Total clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID475007Antibacterial activity against Escherichia coli LCB0012 by two fold serial dilution method2010Bioorganic & medicinal chemistry letters, Apr-01, Volume: 20, Issue:7
Synthesis, crystal and antibacterial studies of diversely functionalized tetrahydropyridin-4-ol.
AID105998In vitro inhibitory activity on MRC5 fibroblast tissue cultures inoculated with virulent RH strain of Toxoplasma gondii2004Bioorganic & medicinal chemistry letters, Jun-07, Volume: 14, Issue:11
Synthesis of new fluoroquinolones and evaluation of their in vitro activity on Toxoplasma gondii and Plasmodium spp.
AID1918194Lipophilicity, log D of the compound2022Journal of medicinal chemistry, 11-10, Volume: 65, Issue:21
Identification of Organic Anion Transporter 2 Inhibitors: Screening, Structure-Based Analysis, and Clinical Drug Interaction Risk Assessment.
AID1888649Antibacterial activity against wild type Staphylococcus aureus assessed as inhibition of bacterial growth2022Bioorganic & medicinal chemistry letters, 02-01, Volume: 57Synthesis and evaluation of dual-action kanglemycin-fluoroquinolone hybrid antibiotics.
AID559556Antimicrobial activity against compound-resistant Coxiella burnetii isolate CP6 obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics.
AID592681Apparent permeability across human Caco2 cell membrane after 2 hrs by LC-MS/MS analysis2011Bioorganic & medicinal chemistry, Apr-15, Volume: 19, Issue:8
QSAR-based permeability model for drug-like compounds.
AID540214Clearance in rat after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID559368Antimicrobial activity against compound-intermediate susceptible Coxiella burnetii isolate CP2 obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics.
AID1557332Toxicity in human assessed as hepatic eosinophilia effect2019MedChemComm, Oct-01, Volume: 10, Issue:10
Quinolone antibiotics.
AID559372Antimicrobial activity against compound-susceptible Coxiella burnetii isolate CP3 obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics.
AID456033Antibacterial activity against Klebsiella pneumoniae type 2 after 18 hrs by twofold microbroth dilution method2009Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19
Design, synthesis and biological evaluations of novel 7-[3-(1-aminocycloalkyl)pyrrolidin-1-yl]-6-desfluoro-8-methoxyquinolones with potent antibacterial activity against multi-drug resistant Gram-positive bacteria.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID410209Antibacterial activity against vancomycin-resistant Enterococcus faecium by broth micro dilution method2008Bioorganic & medicinal chemistry letters, Dec-15, Volume: 18, Issue:24
A facile synthesis, antibacterial, and antitubercular studies of some piperidin-4-one and tetrahydropyridine derivatives.
AID540220Clearance in human after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID1557321Half life in human at 0.3 g, po2019MedChemComm, Oct-01, Volume: 10, Issue:10
Quinolone antibiotics.
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID410207Antibacterial activity against vancomycin and linezolid-resistant Enterococcus faecalis by broth micro dilution method2008Bioorganic & medicinal chemistry letters, Dec-15, Volume: 18, Issue:24
A facile synthesis, antibacterial, and antitubercular studies of some piperidin-4-one and tetrahydropyridine derivatives.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID521102Antimicrobial activity against Streptococcus sp. 'group B' isolate 9 harboring gyrA Ser81Leu mutant, parC Ser79Tyr mutant and parE Ileu495Leu mutant gene by agar dilution method2008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
Emergence of fluoroquinolone resistance in group B streptococcal isolates in Taiwan.
AID164393Antibacterial activity was determined against Pseudomonas aeruginosa PAO1 strain after incubation at 37 degrees C for 18 h2003Journal of medicinal chemistry, Mar-13, Volume: 46, Issue:6
Synthesis and structure-activity relationships of 5-amino-6-fluoro-1-[(1R,2S)-2-fluorocyclopropan-1-yl]-8-methylquinolonecarboxylic acid antibacterials having fluorinated 7-[(3R)-3-(1-aminocyclopropan-1-yl)pyrrolidin-1-yl] substituents.
AID1557282Antibacterial activity against Bacteroides fragilis by agar diffusion method2019MedChemComm, Oct-01, Volume: 10, Issue:10
Quinolone antibiotics.
AID456029Antibacterial activity against Streptococcus pyogenes G-36 after 18 hrs by twofold microbroth dilution method2009Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19
Design, synthesis and biological evaluations of novel 7-[3-(1-aminocycloalkyl)pyrrolidin-1-yl]-6-desfluoro-8-methoxyquinolones with potent antibacterial activity against multi-drug resistant Gram-positive bacteria.
AID1430286Inhibition of Escherichia coli DNA gyrase assessed as inhibition of enzyme-mediated supercoiling of relaxed pHOT1 DNA substrate at 1.95 to 15.6 ug/ml after 30 mins by gel electrophoresis method2017Bioorganic & medicinal chemistry letters, 03-01, Volume: 27, Issue:5
New 1,4-dihydro[1,8]naphthyridine derivatives as DNA gyrase inhibitors.
AID410236Antibacterial activity against Escherichia coli LCB0010 by broth micro dilution method2008Bioorganic & medicinal chemistry letters, Dec-15, Volume: 18, Issue:24
A facile synthesis, antibacterial, and antitubercular studies of some piperidin-4-one and tetrahydropyridine derivatives.
AID410205Antibacterial activity against Enterococcus faecalis by broth micro dilution method2008Bioorganic & medicinal chemistry letters, Dec-15, Volume: 18, Issue:24
A facile synthesis, antibacterial, and antitubercular studies of some piperidin-4-one and tetrahydropyridine derivatives.
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID540231Dose normalised AUC in dog after po administration2005Xenobiotica; the fate of foreign compounds in biological systems, Feb, Volume: 35, Issue:2
Comparative evaluation of oral systemic exposure of 56 xenobiotics in rat, dog, monkey and human.
AID1636356Drug activation in human Hep3B cells assessed as human CYP2C9-mediated drug metabolism-induced cytotoxicity measured as decrease in cell viability at 300 uM pre-incubated with BSO for 18 hrs followed by incubation with compound for 3 hrs in presence of NA2016Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID559551Antimicrobial activity against compound-intermediate susceptible Coxiella burnetii isolate CP4 obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics.
AID237037Dissociation constant (pKa) was determined2005Journal of medicinal chemistry, Aug-11, Volume: 48, Issue:16
A chiral benzoquinolizine-2-carboxylic acid arginine salt active against vancomycin-resistant Staphylococcus aureus.
AID1430300Antibacterial activity against Escherichia coli ATCC 35218 assessed as decrease in ATP level at 1.95 ug/ml after 24 hrs by BacTiter-Glo reagent based bioluminescence assay2017Bioorganic & medicinal chemistry letters, 03-01, Volume: 27, Issue:5
New 1,4-dihydro[1,8]naphthyridine derivatives as DNA gyrase inhibitors.
AID425652Total body clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID444052Hepatic clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID410208Antibacterial activity against Enterococcus faecium by broth micro dilution method2008Bioorganic & medicinal chemistry letters, Dec-15, Volume: 18, Issue:24
A facile synthesis, antibacterial, and antitubercular studies of some piperidin-4-one and tetrahydropyridine derivatives.
AID1918192Inhibition of human OAT2 tv.1 variant expressed in HEK293 cells assessed as inhibition of [3H]cGMP uptake by scintillation analysis2022Journal of medicinal chemistry, 11-10, Volume: 65, Issue:21
Identification of Organic Anion Transporter 2 Inhibitors: Screening, Structure-Based Analysis, and Clinical Drug Interaction Risk Assessment.
AID444057Fraction escaping hepatic elimination in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID540211Fraction unbound in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID476929Human intestinal absorption in po dosed human2010European journal of medicinal chemistry, Mar, Volume: 45, Issue:3
Neural computational prediction of oral drug absorption based on CODES 2D descriptors.
AID456027Antibacterial activity against Staphylococcus epidermidis 56500 after 18 hrs by twofold microbroth dilution method2009Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19
Design, synthesis and biological evaluations of novel 7-[3-(1-aminocycloalkyl)pyrrolidin-1-yl]-6-desfluoro-8-methoxyquinolones with potent antibacterial activity against multi-drug resistant Gram-positive bacteria.
AID206214Antibacterial activity was determined against Staphylococcus epidermis 56500 strain after incubation at 37 degrees C for 18 h2003Journal of medicinal chemistry, Mar-13, Volume: 46, Issue:6
Synthesis and structure-activity relationships of 5-amino-6-fluoro-1-[(1R,2S)-2-fluorocyclopropan-1-yl]-8-methylquinolonecarboxylic acid antibacterials having fluorinated 7-[(3R)-3-(1-aminocyclopropan-1-yl)pyrrolidin-1-yl] substituents.
AID410220Antibacterial activity against Escherichia coli LCB0011 by broth micro dilution method2008Bioorganic & medicinal chemistry letters, Dec-15, Volume: 18, Issue:24
A facile synthesis, antibacterial, and antitubercular studies of some piperidin-4-one and tetrahydropyridine derivatives.
AID474996Antibacterial activity against Staphylococcus aureus LCB0001 by two fold serial dilution method2010Bioorganic & medicinal chemistry letters, Apr-01, Volume: 20, Issue:7
Synthesis, crystal and antibacterial studies of diversely functionalized tetrahydropyridin-4-ol.
AID444053Renal clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID444056Fraction escaping gut-wall elimination in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID410204Antibacterial activity against methicillin-resistant Staphylococcus epidermidis by broth micro dilution method2008Bioorganic & medicinal chemistry letters, Dec-15, Volume: 18, Issue:24
A facile synthesis, antibacterial, and antitubercular studies of some piperidin-4-one and tetrahydropyridine derivatives.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID559363Antimicrobial activity against compound-susceptible Coxiella burnetii Q212 obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics.
AID559362Antimicrobial activity against compound-intermediate susceptible Coxiella burnetii Q212 obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics.
AID588209Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset2010Chemical research in toxicology, Jul-19, Volume: 23, Issue:7
Developing structure-activity relationships for the prediction of hepatotoxicity.
AID202108Tested for in vitro antibacterial activity against Streptococcus pneumoniae W14662003Journal of medicinal chemistry, May-08, Volume: 46, Issue:10
A novel antibacterial 8-chloroquinolone with a distorted orientation of the N1-(5-amino-2,4-difluorophenyl) group.
AID521103Antimicrobial activity against Streptococcus sp. 'group B' isolate 1 harboring gyrA Glu85Lys mutant, parC Ser79Tyr mutant and parE Ileu495Leu mutant gene by agar dilution method2008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
Emergence of fluoroquinolone resistance in group B streptococcal isolates in Taiwan.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID1430292Antibacterial activity against Escherichia coli ATCC 35218 incubated after 24 hrs by resazurin dye based broth microdilution assay2017Bioorganic & medicinal chemistry letters, 03-01, Volume: 27, Issue:5
New 1,4-dihydro[1,8]naphthyridine derivatives as DNA gyrase inhibitors.
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID203449Inhibitory activity against ciprofloxacin resistant staphylococci; Range is 2-8 ug/mL1996Journal of medicinal chemistry, Sep-27, Volume: 39, Issue:20
New directions in antibacterial research.
AID67078Antibacterial activity was determined against Enterococcus faecalis ATCC 19433 strain after incubation at 37 degrees C for 18 h2003Journal of medicinal chemistry, Mar-13, Volume: 46, Issue:6
Synthesis and structure-activity relationships of 5-amino-6-fluoro-1-[(1R,2S)-2-fluorocyclopropan-1-yl]-8-methylquinolonecarboxylic acid antibacterials having fluorinated 7-[(3R)-3-(1-aminocyclopropan-1-yl)pyrrolidin-1-yl] substituents.
AID1557281Antibacterial activity against Klebsiella by agar diffusion method2019MedChemComm, Oct-01, Volume: 10, Issue:10
Quinolone antibiotics.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID475003Antibacterial activity against vancomycin-resistant Enterococcus faecium LCB0008 by two fold serial dilution method2010Bioorganic & medicinal chemistry letters, Apr-01, Volume: 20, Issue:7
Synthesis, crystal and antibacterial studies of diversely functionalized tetrahydropyridin-4-ol.
AID474999Antibacterial activity against methicillin-resistant Staphylococcus epidermidis LCB0004 by two fold serial dilution method2010Bioorganic & medicinal chemistry letters, Apr-01, Volume: 20, Issue:7
Synthesis, crystal and antibacterial studies of diversely functionalized tetrahydropyridin-4-ol.
AID1557288Antibacterial activity against Clostridium perfringens by agar diffusion method2019MedChemComm, Oct-01, Volume: 10, Issue:10
Quinolone antibiotics.
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID559360Antimicrobial activity against compound-susceptible Coxiella burnetii Nine-Mile obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics.
AID444055Fraction absorbed in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID540218Clearance in monkey after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID1557322Protein binding in human at 0.3 g, po2019MedChemComm, Oct-01, Volume: 10, Issue:10
Quinolone antibiotics.
AID456030Antibacterial activity against Streptococcus mitis IID685 after 18 hrs by twofold microbroth dilution method2009Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19
Design, synthesis and biological evaluations of novel 7-[3-(1-aminocycloalkyl)pyrrolidin-1-yl]-6-desfluoro-8-methoxyquinolones with potent antibacterial activity against multi-drug resistant Gram-positive bacteria.
AID1557283Antibacterial activity against Haemophilus influenzae with horse blood by agar diffusion method2019MedChemComm, Oct-01, Volume: 10, Issue:10
Quinolone antibiotics.
AID559559Antimicrobial activity against compound-resistant Coxiella burnetii isolate CP7 obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics.
AID74698Tested for in vitro antibacterial activity against Gram (+) bacteria2003Journal of medicinal chemistry, May-08, Volume: 46, Issue:10
A novel antibacterial 8-chloroquinolone with a distorted orientation of the N1-(5-amino-2,4-difluorophenyl) group.
AID456034Antibacterial activity against Pseudomonas aeruginosa PAO1 after 18 hrs by twofold microbroth dilution method2009Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19
Design, synthesis and biological evaluations of novel 7-[3-(1-aminocycloalkyl)pyrrolidin-1-yl]-6-desfluoro-8-methoxyquinolones with potent antibacterial activity against multi-drug resistant Gram-positive bacteria.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID410202Antibacterial activity against methicillin-resistant Staphylococcus aureus by broth micro dilution method2008Bioorganic & medicinal chemistry letters, Dec-15, Volume: 18, Issue:24
A facile synthesis, antibacterial, and antitubercular studies of some piperidin-4-one and tetrahydropyridine derivatives.
AID475009Antibacterial activity against Klebsiella pneumoniae LCB0014 by two fold serial dilution method2010Bioorganic & medicinal chemistry letters, Apr-01, Volume: 20, Issue:7
Synthesis, crystal and antibacterial studies of diversely functionalized tetrahydropyridin-4-ol.
AID1888648Antibacterial activity against rifampicin resistant Staphylococcus aureus harboring RpoBH481Y mutant assessed as inhibition of bacterial growth2022Bioorganic & medicinal chemistry letters, 02-01, Volume: 57Synthesis and evaluation of dual-action kanglemycin-fluoroquinolone hybrid antibiotics.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (459)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's227 (49.46)18.2507
2000's166 (36.17)29.6817
2010's56 (12.20)24.3611
2020's10 (2.18)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 39.34

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index39.34 (24.57)
Research Supply Index6.24 (2.92)
Research Growth Index4.27 (4.65)
Search Engine Demand Index59.70 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (39.34)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials47 (10.09%)5.53%
Trials0 (0.00%)5.53%
Reviews31 (6.65%)6.00%
Reviews0 (0.00%)6.00%
Case Studies15 (3.22%)4.05%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Other373 (80.04%)84.16%
Other11 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
[NCT00548002]430 participants (Actual)Observational1999-01-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]